HIGHLIGHTS
SUMMARY
Entrectinib is a potent, central nervous system (CNS)active inhibitor of tyrosine receptor kinases (TRK) A, B and C, ROS proto-oncogene 1 receptor tyrosine kinase, and anaplastic lymphoma kinase (ALK). A comparison between the pharmacokinetics in pediatric and adult patients (from STARTRK-1) suggested that pediatric patients receiving 400 mg/m2 QD entrectinib using the non-acidulant containing F1 formulation had lower exposures compared to adults receiving the same dose/formulation and also lower exposures than adults receiving the recommended flat dose of 600 mg QD (F2A) (approximately 300 mg/m2 for a . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.